Marijuana, alcohol abuse accelerate brain aging: study
By
Lois A. Bowers
Aug 22, 2018
Cannabis and alcohol abuse accelerate brain aging, according to what is thought to be the largest brain imaging study ever conducted.
Tau PET performs well in predicting dementia in individuals with MCI
Jun 12, 2024
Tau positron emission tomography predicts all-cause dementia and Alzheimer disease dementia
Transcranial direct current stimulation beneficial in Alzheimer’s disease
Dec 07, 2023
Active tCDS improves cognitive functions in memory domain, including word recall, recall of test instructions and word recognition.
Alzheimer’s care isn’t working; here’s what is
By
Pamela Reese
Aug 29, 2019
There are several reasons that I don’t believe Alzheimer’s care is where it should be. Here are six.
Risk for adverse outcomes increased with antipsychotic use in dementia
Apr 19, 2024
Risks increased for stroke, venous thromboembolism, myocardial infarction, heart failure, fracture, pneumonia and acute kidney injury.
New model predicts five-year Alzheimer’s dementia risk
Oct 12, 2022
The model includes demographic information, brain imaging test results and genetic biomarkers.
Number of teeth, periodontitis in older adults linked to hippocampal atrophy
Jul 06, 2023
A qualitative interaction was seen between the number of teeth present and the mean periodontal probing depth for symmetric percentage change in left hippocampus.
Excess mortality seen for seniors with Alzheimer’s disease, dementia in COVID-19
Mar 08, 2022
Enrollees with Alzheimer’s disease and related dementias had increased adjusted mortality, especially for Asian, Black and Hispanic populations.
Senate passes spending bill with $425 million boost for Alzheimer’s research
By
Lois A. Bowers
Aug 24, 2018
Alzheimer’s and dementia research funding in fiscal year 2019 at the National Institutes of Health would see a $425 million increase to a total of $2.3 billion under a bill passed Thursday by the...
Solanezumab does not slow cognitive decline in preclinical Alzheimer’s disease
Jul 19, 2023
The mean change in Preclinical Alzheimer Cognitive Composite score not significantly different at 240 weeks with solanezumab or placebo.